28
Jul 22
Spexis provides business update
ALLSCHWIL, Switzerland, July 28, 2022 – Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today provides a business update, including development programs’ progress and its efforts to secure funding for these projects. Cash position to finance operations extended into January 2023 Resources focused…